Our data indicated that treatment with QNZ to inhibit the NF-κB signaling and attenuate the severity of SLE suggests that the NF-κB signaling may be a therapeutic target for intervention of SLE. The gene discussed is NFKB1; the disease is systemic lupus erythematosus.